NAVB Navidea Biopharmaceuticals Inc.

0.17
0  -2%
Previous Close 0.17
Open 0.17
Price To Book 16.6
Market Cap 30193856
Shares 181,890,700
Volume 467,269
Short Ratio 13.82
Av. Daily Volume 631,144

SEC filingsSee all SEC filings

  1. 8-K - Current report 19620478
  2. 8-K - Current report 19557752
  3. S-8 - Securities to be offered to employees in employee benefit plans 181248962
  4. 8-K - Current report 181210936
  5. 8-K - Current report 181206396

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved March 13, 2013.
Lymphoseek
Lymphatic-tissue tracing agent
Phase 3 - seeking partner to continue development
NAV4694
Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI)
Approved June 13, 2014.
Lymphoseek
Head and Neck Cancer
Phase 1/2 initiated February 2017. Enrolling as of November 2017.
Lymphoseek
Rheumatoid arthritis

Latest News

  1. Navidea Biopharmaceuticals Announces Extension of NYSE American Listing
  2. Navidea Biopharmaceuticals Announces Decision by Ohio Supreme Court
  3. Navidea Biopharmaceuticals Announces Patent Extension for Lymphoseek®
  4. Edited Transcript of NAVB earnings conference call or presentation 7-Nov-18 9:30pm GMT
  5. Navidea Biopharmaceuticals Appoints Adam Cutler to Board of Directors
  6. Navidea Biopharmaceuticals Appoints Dr. Michael Rosol as Chief Medical Officer
  7. Navidea Biopharmaceuticals to Present at the 11th Annual LD Micro Event 2018
  8. Navidea Biopharmaceuticals Announces Presentation at the Radiological Society of North America (RSNA) 104th Scientific Assembly and Annual Meeting 2018
  9. Navidea Biopharmaceuticals Appoints Dr. Kathy Rouan to Board of Directors
  10. Navidea: 3Q Earnings Snapshot
  11. Navidea Biopharmaceuticals Reports Third Quarter 2018 Financial Results
  12. Navidea Biopharmaceuticals Schedules Third Quarter 2018 Earnings Conference Call and Business Update
  13. Navidea Biopharmaceuticals Wins Dismissal of Platinum Litigation
  14. Navidea Biopharmaceuticals Receives Acceptance Letter from NYSE American
  15. Navidea Biopharmaceuticals to Present Data on the Manocept Platform at 2018 ACR Annual Meeting
  16. Navidea Biopharmaceuticals to Present at the 2018 BIO Investor Forum
  17. The Daily Biotech Pulse: Morphosys Expands Collaboration, Osiris Announces Product Launch, Argenx To Offer Shares
  18. Navidea Biopharmaceuticals Announces Acceptance into the National Institutes of Health Commercialization Accelerator Program
  19. Navidea Biopharmaceuticals Announces Closing of a $3 Million Private Placement

SEC Filings

  1. 8-K - Current report 19620478
  2. 8-K - Current report 19557752
  3. S-8 - Securities to be offered to employees in employee benefit plans 181248962
  4. 8-K - Current report 181210936
  5. 8-K - Current report 181206396
  6. 10-Q - Quarterly report [Sections 13 or 15(d)] 181172678
  7. 8-K - Current report 181166683
  8. 8-K - Current report 181155826
  9. 8-K - Current report 181147547
  10. 8-K - Current report 181112170